Dexmedetomidine Versus Midazolam for Facilitating Extubation

Completed · Not applicable

Conditions studied: Critical Illness

In brief

The purpose of this randomized, double-blind study is to evaluate the utility, safety, and cost of transitioning benzodiazepine sedation to dexmedetomidine in medical or surgical intensive care unit (ICU) patients requiring sedation when tracheal extubation is nearing. Fifty medical or surgical ICU patients requiring sedation with existing benzodiazepine therapy and qualifying for daily awakenings will be randomized in a double-blind manner to receive additional midazolam or dexmedetomidine.

Key facts

Study ID

NCT00744380

Run by

University of Colorado, Denver

People needed

23

Starts

2008-08-01

Expected to finish

2012-10-01

Last updated by the study team

2016-09-28

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients requiring mechanical ventilation in the medical or surgical ICUs.
• Currently receiving lorazepam or midazolam by continuous infusion for the purpose of sedation therapy.
• Sedation in these ICUs is provided using an ICU-wide order form that preferentially uses either lorazepam or midazolam with the infusion rate titrated by the bedside nurse to the desired Riker sedation-agitation score(s). Continuous analgesia is provided with fentanyl only with the infusion rate titrated by the bedside nurse to PABS ≤ 3 .
• Anticipated duration of continuous sedation > 12 hours with the level of sedation expected to be maintained at Riker sedation-agitation score(s) of 3 - 4.
• Patients qualifying for daily awakenings as determined by all of the following:
• fraction of inspired oxygen (FiO2) ≤ 70% or
• positive end expiratory pressure (PEEP) ≤ 14 cmH2O,
• hemodynamically stable, and
• NOT receiving pharmacologic neuromuscular blockade.
• Informed consent and HIPAA authorization within 24 hours of qualifying for daily awakenings.

You may not qualify if…

• Patients < 18 years of age or > 85 years of age.
• Patients receiving intermittent or "as needed" administration of lorazepam or midazolam.
• Patients receiving lorazepam or midazolam for purposes other than sedation (e.g. seizure control).
• Patients receiving epidural administration of medication(s).
• Patients with Childs-Pugh class C liver disease.
• Comatose patients by metabolic or neurologic affectation.
• Patients with active myocardial ischemia or second- or third-degree heart block.
• Moribund state with planned withdrawal of life support.
• Patients with known or suspected severe adverse reactions to midazolam (or any other benzodiazepine) or dexmedetomidine (or clonidine).
• Patients with alcohol abuse within six months of study eligibility.
• Pregnant females or females suspected of being pregnant.

Where it is running

• University of Colorado Hospital — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.